Bank of New York Mellon
RARX

Bank of New York Mellon’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bank of New York Mellon’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-137,886
Closed -$6.62M – 4226
2020
Q1 		$6.62M Sell
137,886
-1,102
-0.8% -$51.3K ﹤0.01% 1924
2019
Q4 		$6.52M Sell
138,988
-30,514
-18% -$1.35M ﹤0.01% 2201
2019
Q3 		$4.01M Buy
169,502
+11,302
+7% +$335K ﹤0.01% 2390
2019
Q2 		$4.76M Buy
158,200
+19,785
+14% +$453K ﹤0.01% 2355
2019
Q1 		$3.1M Buy
138,415
+60,597
+78% +$1.3M ﹤0.01% 2562
2018
Q4 		$1.42M Buy
77,818
+24,059
+45% +$378K ﹤0.01% 2911
2018
Q3 		$973K Buy
53,759
+5,797
+12% +$68.7K ﹤0.01% 3276
2018
Q2 		$478K Sell
47,962
-3,864
-7% -$26.7K ﹤0.01% 3652
2018
Q1 		$275K Buy
51,826
+14,383
+38% +$103K ﹤0.01% 3830
2017
Q4 		$318K Buy
37,443
+358
+1% +$4.4K ﹤0.01% 3777
2017
Q3 		$542K Sell
37,085
-847
-2% -$12.8K ﹤0.01% 3551
2017
Q2 		$711K Buy
37,932
+13,881
+58% +$313K ﹤0.01% 3435
2017
Q1 		$512K Buy
24,051
+10,493
+77% +$201K ﹤0.01% 3547
2016
Q4 		$206K Buy
+13,558
New +$184K ﹤0.01% 3898

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Bank of New York Mellon's RARX Position: Q2 2020 in Review

Bank of New York Mellon sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 137,886 shares — an estimated $6.62M sold.

Bank of New York Mellon first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $6.62M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Bank of New York Mellon reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bank of New York Mellon sold 137,886 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $6.62M.
  • Bank of New York Mellon first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • Bank of New York Mellon's Ra Pharmaceuticals, Inc. Common Stock position peaked at $6.62M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Bank of New York Mellon's 13F filing for Q2 2020, filed 12 Aug 2020.